CSL Limited (ASX:CSL – Get Free Report) insider Alison Watkins acquired 214 shares of the stock in a transaction dated Tuesday, February 17th. The stock was acquired at an average price of A$151.56 per share, for a total transaction of A$32,432.98.
CSL Stock Performance
The company has a debt-to-equity ratio of 64.46, a quick ratio of 1.68 and a current ratio of 1.86. The stock has a market cap of $77.43 billion, a PE ratio of 28.02, a P/E/G ratio of 1.29 and a beta of 0.32.
CSL Dividend Announcement
The business also recently declared a Interim dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Wednesday, April 8th will be given a $1.837 dividend. The ex-dividend date is Monday, March 9th. This represents a yield of 121.0%. CSL’s dividend payout ratio is presently 50.38%.
About CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology.
See Also
- Five stocks we like better than CSL
- The gold chart Wall Street is terrified of…
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- New gold price target
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
